Carregant...
The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
OBJECTIVE: The aim of this study was to evaluate the budget impact of introducing tildrakizumab for moderate-to-severe plaque psoriasis from a US health plan perspective. METHODS: A budget impact model estimated costs before and after the adoption of tildrakizumab to a hypothetical US health plan wi...
Guardat en:
| Publicat a: | Pharmacoecon Open |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7688845/ https://ncbi.nlm.nih.gov/pubmed/32219733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-020-00208-9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|